Urodynamix Technologies Ltd. Closes $1.5 Million Private Placement

Urodynamix Technologies Ltd. (TSX VENTURE:URO) is pleased to announce that it
has closed a $1.5 million non-brokered private placement for 30,000,000 common
shares previously reported on September 11, 2009. BC Advantage Funds (VCC) Ltd.
subscribed for $750,000 and management and directors subscribed for $238,675 of
the $1.5 million placement.


The Company will offer an additional 10,000,000 common shares to third parties
at a price of $0.05. No commission was payable on the 15,000,000 common shares
issued to BC Advantage Funds under the first closing of the private placement.
The Company will pay a commission of up to 7.5% on sales of common shares to
third parties. All of the common shares issued under the private placement are
subject to a four month resale restriction.


About Urodynamix Technologies Ltd.

Urodynamix Technologies is a Canadian medical device company developing and
commercializing non-invasive medical technology based on proprietary
applications of near-infrared spectroscopy (NIRS). The Company is currently
focused on products that aid in the diagnosis and treatment of urinary
incontinence, lower urinary tract symptoms, erectile dysfunction, prostate
cancer, benign prostatic hyperplasia, and traumatic increases in intra-abdominal
pressure that cause abdominal compartment syndrome. Urodynamix's breakthrough
medical technology has the potential to beneficially affect more than 200
million people worldwide.


Certain information contained in this press release may be forward-looking and
is subject to unknown risks, which could cause actual results to differ
materially from those set forth or implied herein. Although the Company believes
that the expectations reflected in such forward-looking statements are
reasonable, it can give no assurance that such expectations will prove correct.